Shikonin-mediated up-regulation of miR-34a and miR-202 inhibits retinoblastoma proliferation (Publication with Expression of Concern)

被引：22

作者：

Su, Yan ^{[1
]}

Lu, Shiyou ^{[2
]}

Li, Jincun ^{[3
]}

Deng, Liya ^{[1
]}

机构：

[1] Jinan Second Peoples Hosp, Dept TCM Ophthalmol, 148 Jingyi Rd, Jinan 250001, Shandong, Peoples R China

[2] Shandong Univ TCM, Dept Acupuncture, Affiliated Hosp, 42 Wenhua West Rd, Jinan 250011, Shandong, Peoples R China

[3] Shandong Prov Western Hosp, Dept TCM, 4 Duanxing West Rd, Jinan 250022, Shandong, Peoples R China

来源：

TOXICOLOGY RESEARCH | 2018年 / 7卷 / 05期

关键词：

CANCER-CELLS; TUMOR-SUPPRESSOR; TARGETING STAT3; BREAST-CANCER; LUNG-CANCER; EXPRESSION; APOPTOSIS; PATHWAY; GROWTH; NEUROBLASTOMA;

D O I：

10.1039/c8tx00079d

中图分类号：

R99 [毒物学（毒理学）];

学科分类号：

100405 ;

摘要：

Retinoblastoma (RB) is an ocular tumor that occurs mainly in children. The pathogenesis of RB is not well understood, and its treatment strategies are very limited. Shikonin is widely reported as an anti-tumor agent. However, its effect on RB is still unknown. MTT assay was performed to detect the proliferation ability of two RB cell lines, Y-79 and WERI-Rb-1, upon treatment with Shikonin. Colony formation assay was conducted to examine the clonogenic ability of Shikonin-treated cells. Real-time PCR and western blotting were performed for expression analysis of miRNAs and MYCN, respectively. Luciferase activity assay was conducted to test the inhibition mechanism of miR-34a and miR-202 on MYCN. Shikonin could effectively inhibit the proliferation of RB cells and upregulate the expressions of miR-34a and miR-202. MiR-34a and miR-202 could directly target the mRNA degradation of oncogene MYCN, and the inhibitory effect of Shikonin was largely weakened by restoring the MYCN protein expression. Shikonin-mediated up-regulation of miR-34a and miR-202 inhibits RB proliferation, partially mediated through MYCN.

引用

页码：907 / 912

页数：6

共 29 条

[1] Loss of Estrogen-Regulated microRNA Expression Increases HER2 Signaling and Is Prognostic of Poor Outcome in Luminal Breast Cancer [J].